Torii Pharmaceuticals Start Phase II/III In Hyposensitization Therapy
This article was originally published in PharmAsia News
Torii Pharmaceuticals announced July 31 it started Phase II clinical trials for TO-203, a hyposensitization drug for allergic asthma and rhinitis caused by house dust mites. The sublingual tablets extract protein from the allergen.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.